NASHVILLE, Tenn., May 8, 2017 /PRNewswire/ -- Cumberland
Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it
will release first quarter 2017 financial results after the market
closes on Monday, May 15, 2017.
A conference call and live Internet webcast will be held on
Monday, May 15, 2017, at 4:30 p.m. Eastern Time to discuss the
results.
To participate in the call, please dial 877-303-1298 (for U.S.
callers) or 253-237-1032 (for international callers). A
rebroadcast of the teleconference will be available for one week
and can be accessed by dialing 855-859-2056 (for U.S. callers) or
404-537-3406 (for international callers). The Conference ID
for the rebroadcast is 11376419. The live webcast and rebroadcast
can be accessed via Cumberland's
website at http://investor.shareholder.com/cpix/events.cfm.
Cumberland Pharmaceuticals Inc. is a specialty
pharmaceutical company focused on acquisition, development, and
commercialization of branded prescription products. The Company's
primary target markets include hospital acute care and
gastroenterology. Cumberland's six
marketed products include
Acetadote® (acetylcysteine) Injection for
the treatment of acetaminophen poisoning,
Caldolor® (ibuprofen) Injection, for the
treatment of pain and fever,
Kristalose® (lactulose) for Oral Solution, a
prescription laxative,
Vaprisol® (conivaptan) Injection, for the
treatment of hyponatremia and Omeclamox-Pak® for
the treatment of H. pylori infection and duodenal
ulcer disease, and Ethyol® (amifostine) for
Injection, for the treatment of oncology patients. Cumberland is developing
Hepatoren® (ifetroban)
Injection for the treatment of Hepatorenal Syndrome,
Boxaban® (ifetroban) Oral Capsule for the
treatment of Aspirin-Exacerbated Respiratory Disease,
Vasculan™ (ifetroban) Oral Capsule for the
treatment of systemic sclerosis, and Portaban™, for the
treatment of portal hypertension. Cumberland is dedicated to providing
innovative products that improve quality of care for patients. For
more information on Cumberland's
approved products, including full prescribing information, please
visit the individual product websites, links to which can be found
on the Company's website at www.cumberlandpharma.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-first-quarter-2017-financial-results-300453031.html
SOURCE Cumberland Pharmaceuticals Inc.